Date Title and Summary Additional Formats
Nov 14, 2023
PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
Nov 07, 2023
Monthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023
Oct 24, 2023
PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
Oct 23, 2023
TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation
Oct 23, 2023
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2023
Oct 09, 2023
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains
Oct 04, 2023
PHAXIAM Receives Compliance Notice from Nasdaq
Oct 03, 2023
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration
Sep 26, 2023
Rapport Financier Semestriel 30 Juin 2023 PHAXIAM
Sep 21, 2023
PHAXIAM Provides Business and Financial Update For the First Half of 2023